Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 6, 2016, Pages 800-805

  Lee, S S ^a   Lee, C M ^a   Kim, T H ^a   Kim, J J ^a   Lee, J M ^a   Kim, H J ^a   Ha, C Y ^a   Jung, W T ^a   Lee, O J ^a   Kim, D Y ^b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Mokpo National Hospital   (South Korea)

Author keywords

Alcoholic liver disease; Dili; Hepatitis B; Hepatitis C; MDR TB

Indexed keywords

AMINOSALICYLIC ACID; ASPARTATE AMINOTRANSFERASE; CYCLOSERINE; LINEZOLID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOXIC HEPATITIS; TREATMENT OUTCOME; FOLLOW UP; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; ANTITUBERCULAR AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS C; HUMANS; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84966460599     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0668     Document Type: Article

References (33)

1. World Health Organization Global tuberculosis report, 2013 WHO/HTM/TB/2013.11 Geneva, Switzerland: WHO, 2013.
2. Mukherjee J S, Rich M L, Socci A R, et al Programmes and principles in treatment of multidrug-resistant tuberculosis Lancet 2004; 363: 474-481.
3. Furin J J, Mitnick C D, Shin S S, et al Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 2001; 5: 648-655.
4. Keshavjee S, Gelmanova I Y, Shin S S, et al Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome Int J Tuberc Lung Dis 2012; 16: 596-603.
5. Sharma S K.Anti-tuberculosis drugs and hepatotoxicity Infect Genet Evol 2004; 4: 167-170.
6. Shin S S, Pasechnikov A D, Gelmanova I Y, et al Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia Int J Tuberc Lung Dis 2007; 11: 1314-1320.
7. Törün T, Gungor G, Ozmen I, et al Side effects associated with the treatment of multidrug-resistant tuberculosis Int J Tuberc Lung Dis 2005; 9: 1373-1377.
8. Dossing M, Wilcke J T, Askgaard D S, Nybo B.Liver injury during antituberculosis treatment: an 11-year study Tubercle Lung Dis 1996; 77: 335-340.
9. Pande J N, Singh S P, Khilnani G C, Khilnani S, Tandon R K.Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study Thorax 1996; 51: 132-136.
10. Fernandez-Villar A, Sopena B, Fernandez-Villar J, et al The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity Int J Tuberc Lung Dis 2004; 8: 1499-1505.
11. Lomtadze N, Kupreishvili L, Salakaia A, et al Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis PLOS ONE 2013; 8: e83892.
12. Ungo J R, Jones D, Ashkin D, et al Anti-tuberculosis druginduced hepatotoxicity The role of hepatitis C virus and the human immunodeficiency virus Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1871-1876.
13. Chien J Y, Huang R M, Wang J Y, et al Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment Int J Tuberc Lung Dis 2010; 14: 616-621.
14. Kwon Y S, Koh W J, Suh G Y, Chung M P, Kim H, Kwon O J.Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy Chest 2007; 131: 803-808.
15. Liu Y M, Cheng Y J, Li Y L, Liu C E, Hsu W H.Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis Lung 2014; 192: 205-210.
16. Lee B H, Koh W J, Choi M S, et al Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy Chest 2005; 127: 1304-1311.
17. Aithal G P,Watkins P B, Andrade R J, et al Case definition and phenotype standardization in drug-induced liver injury Clin Pharmacol Ther 2011; 89: 806-815.
18. World Health Organization Treatment of tuberculosis: guidelines 4th ed WHO/HTM/TB/2009.420 Geneva, Switzerland: WHO, 2010.
19. Gulbay B E, Gurkan O U, Yildiz O A, et al Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis Respir Med 2006; 100: 1834-1842.
20. TelemanM D, Chee C B, Earnest A,Wang Y T.Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore Int J Tuberc Lung Dis 2002; 6: 699-705.
21. Shang P, Xia Y, Liu F, et al Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China PLOS ONE 2011; 6: e21836.
22. Sun H Y, Chen Y J, Gau C S, Chang S C, Luh K T.A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature J Formos Med Assoc 2009; 108: 102-111.
23. Leimane V, Riekstina V, Holtz T H, et al Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study Lancet 2005; 365: 318-326.
24. Suarez P G, Floyd K, Portocarrero J, et al Feasibility and costeffectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru Lancet 2002; 359: 1980-1989.
25. Tahaoglu K, Torun T, Sevim T, et al The treatment of multidrug-resistant tuberculosis in Turkey N Engl JMed 2001; 345: 170-174.
26. Hsu H L, Bai K J, Chiang Y C, Lin S J, Yu M C.Hepatitis associated with prothionamide for treatment of multidrugresistant tuberculosis J FormosMed Assoc 2010; 109: 923-927.
27. Sochocky S.Acute hepatitis due to para-Aminosalicylic acid Br J Clin Pract 1971; 25: 179-182.
28. Aristoff P A, Garcia G A, Kirchhoff P D, Showalter H D.Rifamycins-obstacles and opportunities Tuberculosis 2010; 90: 94-118.
29. De Bus L, Depuydt P, Libbrecht L, et al Severe drug-induced liver injury associated with prolonged use of linezolid J Med Toxicol 2010; 6: 322-326.
30. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I,Menzies D.Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis AmJ Respir Crit Care Med 2003; 167: 1472-1477.
31. Schaberg T, Rebhan K, Lode H.Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis Eur Respir J 1996; 9: 2026-2030.
32. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin N Engl J Med 1993; 328: 527-532.
33. Chiang C-Y, Enarson D A, Yu M C, et al Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Eur Respir J 2006; 28: 980-985.